Startup Funding News
Explore funding rounds, the companies behind them and the investors taking part.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| CT Develops treatments for serious respiratory diseases | $180M | Growth | Biotech | United States | Investors | |
| XB Xellar BiosystemsCompany profile Develops 3D human tissue models for drug discovery and testing using Organ-on-a-Chip technology Develops 3D human tissue models for drug discovery and testing using Organ-on-a-Chip technology | $50M | Series A | Biotech | United States | Investors Undisclosed | |
| LL Leyden LaboratoriesCompany profile Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections. Develops antibody-based nasal sprays intended to prevent influenza and other respiratory-virus infections. | €40M | Series B | Biotech | Netherlands | Investors | |
| T TissiumCompany profile Develops biomorphic programmable polymers that repair nerves and tissue without stitches Develops biomorphic programmable polymers that repair nerves and tissue without stitches | €30M | Series D+Series C+ | Biotech, Healthtech | France | Investors | |
| OB Ollin BiosciencesCompany profile Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD Develops bispecific antibody therapies for retinal vascular diseases including diabetic macular edema and wet AMD | $330M | Series B | Biotech | United States | Investors | |
| AN Anodyne NanotechCompany profile Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections Develops transdermal microneedle patches delivering GLP-1 and biologic therapeutics without injections | $12.6M | Series A | Biotech | United States | Investors | |
| RB RQ BioCompany profile Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients Develops antibody therapies to prevent seasonal influenza in high-risk and immunocompromised patients | $115M | Series A | Biotech | United Kingdom | Investors | |
| RH Rapalogix HealthCompany profile Develops prescription therapeutics and skincare products for cellular longevity and skin health Develops prescription therapeutics and skincare products for cellular longevity and skin health | $20M | Series A | Biotech | United States | Investors | |
| TT TRIMTECH TherapeuticsCompany profile Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases | $47M | Seed+Seed | Biotech | United Kingdom | Investors | |
| NB NorthLinks BioCompany profile Develops broad-spectrum antiviral prophylactic therapies for respiratory infections Develops broad-spectrum antiviral prophylactic therapies for respiratory infections | $34M | Undisclosed | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.
Browse rounds by topic
Geography
Featured selections
Nordic Foodtech Fund II pairs early capital with scientific expertise
An EIF pledge of up to €30m supports a fund targeting €80m for science-led agrifood companies.
Read the research →